Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolon for Duchenne muscular dystrophy (real-world, Phase 4, single-arm, China)
ChiCTR2400091210Phase 4Not yet recruiting
- Sponsor
- Yuan Xiao
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by Yuan Xiao. Primary endpoints: North Star Ambulatory Assessment (NSAA) at 12 months, 6-minute walking test (6MWT) at 12 months and 1 more. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ChiCTR2400091210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091210.